About our research
The main focus of the group is to implement new genetic tools in the management of patients with MDS during the transplantation process. Magnus Tobiasson is coordinating the Nordic MDS group study NMDSG14B. The research is aimed at developing and evaluating individual minimal residual disease (MRD) markers for early detection of relapse after allogeneic stem cell transplantation. The study has generated several spin-off projects such as evaluation of MRD on sorted stem and progenitor cells, and evaluation of the importance of achieving clonal reduction prior to transplantation.